PCMC
VRTX icon

Planning Capital Management Corporation’s Vertex Pharmaceuticals VRTX Stock Holding History

Planning Capital Management Corporation’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$466 Hold
1
– – ﹤0.01% 672
2024
Q2 		$469 Buy
+1
New +$434 ﹤0.01% 626

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Planning Capital Management Corporation's VRTX Position: Q3 2024 in Review

Planning Capital Management Corporation held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2024 at 1 share worth $466. The position accounts for ﹤0.01% of the portfolio, ranked #672.

Planning Capital Management Corporation first reported a position in VRTX in Q2 2024 and has held it in 2 quarters since. The position peaked at $469 in Q2 2024. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Planning Capital Management Corporation held 1 share of Vertex Pharmaceuticals worth $466 as of Q3 2024.
  • Planning Capital Management Corporation left its Vertex Pharmaceuticals share count unchanged in Q3 2024.
  • Vertex Pharmaceuticals made up ﹤0.01% of Planning Capital Management Corporation's portfolio in Q3 2024, its #672 holding.
  • Planning Capital Management Corporation first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 2 quarters since.
  • Planning Capital Management Corporation's Vertex Pharmaceuticals position peaked at $469 in Q2 2024.
  • 1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Planning Capital Management Corporation's 13F filing for Q3 2024, filed 6 Nov 2024.